A randomized, open-label, phase 3 study of nivolumab in combination with ipilimumab vs extreme regimen (cetuximab + cisplatin/carboplatin + fluorouracil) as first-line therapy in patients with recurrent or metastatic squamous cell carcinoma of the head and neck-CheckMate 651
Saved in:
Published in | Annals of oncology Vol. 27; p. vi350 |
---|---|
Main Authors | , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Elsevier Ltd
01.10.2016
|
Online Access | Get full text |
Cover
Loading…
ISSN: | 0923-7534 1569-8041 |
---|---|
DOI: | 10.1093/annonc/mdw376.68 |